Internal Reference Number: FOI_7885
Date Request Received: 12/04/2024 00:00:00
Date Request Replied To: 08/05/2024 00:00:00
This response was sent via: By Email
Request Summary: Multiple Myeloma
Request Category: Companies
| Question Number 1: Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. | |
| Answer To Question 1: There are 69 separate patients | |
| Question Number 2: Of the multiple myeloma patients over the past 6 months, how many were treated with the following: • Belantamab Mafodotin [Blenrep] • Bortezomib [Velcade] monotherapy or with dexamethasone • Bortezomib, thalidomide and dexamethasone [VTD] • Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) • Carfilzomib [Kyprolis] and dexamethasone • Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone • Daratumumab [Darzalex] monotherapy • Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) • Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) • Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone • Elranatamab • Idecabtagene vicleucel [Abecma] • Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) • Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd) • Lenalidomide [Revlmid] monotherapy • Lenalidomide [Revlimid] and dexamethasone • Pomalidomide [Imnovid] and dexamethasone • Selinexor and dexamethasone • Talquetamab • Teclistamab [Tecvayli] • Any other systemic anti-cancer therapyThanks very much. | |
| Answer To Question 2: • Belantamab Mafodotin [Blenrep] < 5 patients • Bortezomib [Velcade] monotherapy or with dexamethasone 0 patients • Bortezomib, thalidomide and dexamethasone [VTD] 0 patients • Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) <5 patients • Carfilzomib [Kyprolis] and dexamethasone 0 patients • Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone <5 patients • Daratumumab [Darzalex] monotherapy 0 patients • Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) 17 patients • Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) 9 patients • Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone 8 patients • Elranatamab 0 patients • Idecabtagene vicleucel [Abecma] 0 patients • Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) < 5 patients • Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd) 12 patients • Lenalidomide [Revlmid] monotherapy 18 patients • Lenalidomide [Revlimid] and dexamethasone 0 patients • Pomalidomide [Imnovid] and dexamethasone 0 patients • Selinexor and dexamethasone 0 patients • Talquetamab 0 patients • Teclistamab [Tecvayli] 0 patients • Any other systemic anti-cancer therapy No | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
